Terms: = Breast cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
84 results:
1. [Mid-term analysis of prospective cohort study of rivaroxaban in preventing CRT in breast cancer].
Sang D; Fan SM; Li SY; Zhang JT; Wang HM; Zhao XH; Zheng LJ; Liang P; Xi GB; Zhao LM; Zhang YR; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):256-262. PubMed ID: 38494772
[No Abstract] [Full Text] [Related]
2. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R; De Sanctis R; Jacobs F; Benvenuti C; Gaudio M; Saltalamacchia G; Torrisi R; Masci G; Miggiano C; Agustoni F; Pedrazzoli P; Santoro A; Zambelli A
Crit Rev Oncol Hematol; 2024 Apr; 196():104324. PubMed ID: 38462150
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the treatment of cancer.
Wang Y; Wang C; Liu T; Qi H; Chen S; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
J Med Chem; 2024 Jan; 67(1):420-432. PubMed ID: 38146659
[TBL] [Abstract] [Full Text] [Related]
4. Anti-breast cancer activity of biosynthesized selenium nanoparticles using Bacillus coagulans supernatant.
Khaledizade E; Tafvizi F; Jafari P
J Trace Elem Med Biol; 2024 Mar; 82():127357. PubMed ID: 38103517
[TBL] [Abstract] [Full Text] [Related]
5. Cardiometabolic comorbidities in Hispanic/Latino cancer survivors: prevalence and impact on health-related quality of life and supportive care needs.
Maras AF; Penedo FJ; Ramirez AG; Worch SM; Ortiz MS; Yanez B; Munoz E; Lad T; Hollowell C; Medina HN; Moreno PI
Support Care Cancer; 2023 Nov; 31(12):711. PubMed ID: 37982906
[TBL] [Abstract] [Full Text] [Related]
6. Using Radiomics to Differentiate Brain Metastases From Lung cancer Versus breast cancer, Including Predicting Epidermal Growth Factor Receptor and human Epidermal Growth Factor Receptor 2 Status.
Shi J; Chen H; Wang X; Cao R; Chen Y; Cheng Y; Pang Z; Huang C
J Comput Assist Tomogr; 2023 Nov-Dec 01; 47(6):924-933. PubMed ID: 37948368
[TBL] [Abstract] [Full Text] [Related]
7. Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer.
Tsoi H; Lok J; Man EP; Cheng CN; Leung MH; You CP; Chan SY; Chan WL; Khoo US
J Pathol; 2023 Oct; 261(2):156-168. PubMed ID: 37555303
[TBL] [Abstract] [Full Text] [Related]
8. Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling.
Abdullahi SH; Uzairu A; Shallangwa GA; Uba S; Umar AB
J Egypt Natl Canc Inst; 2023 Aug; 35(1):24. PubMed ID: 37544974
[TBL] [Abstract] [Full Text] [Related]
9. Fabrication, optimization, and characterization of pH-responsive PEGylated nanoniosomes containing gingerol for enhanced treatment of breast cancer.
Asghari Lalami Z; Tafvizi F; Naseh V; Salehipour M
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3867-3886. PubMed ID: 37368028
[TBL] [Abstract] [Full Text] [Related]
10.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract] [Full Text] [Related]
11. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
12. Rethinking on the management strategy of malignant phyllodes tumor of the breast: An analysis based on the SEER database.
Chen C; Huang X; Xu Y; Sun Q
Medicine (Baltimore); 2023 Mar; 102(12):e33326. PubMed ID: 36961178
[TBL] [Abstract] [Full Text] [Related]
13. ccne1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic breast cancer.
Guerrero-Zotano Á; Belli S; Zielinski C; Gil-Gil M; Fernandez-Serra A; Ruiz-Borrego M; Ciruelos Gil EM; Pascual J; Muñoz-Mateu M; Bermejo B; Margeli Vila M; Antón A; Murillo L; Nissenbaum B; Liu Y; Herranz J; Fernández-García D; Caballero R; López-Guerrero JA; Bianco R; Formisano L; Turner N; Martín M
Clin Cancer Res; 2023 Apr; 29(8):1557-1568. PubMed ID: 36749874
[TBL] [Abstract] [Full Text] [Related]
14. [Differential diagnosis model of benign and malignant breast BI-RADS category 4 nodules based on serum SP70 and conventional laboratory indicators].
Ding HM; Xu J; Wang F; Zhang Q; Pan H; Mu Y; Gu CR; Miao SX; Li XN; Ju HY; Wang L; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Dec; 56(12):1774-1783. PubMed ID: 36536565
[No Abstract] [Full Text] [Related]
15. Comparison of p63 immunohistochemistry and shear wave elastography in the diagnosis of indeterminate breast lesions: A prospective study.
Sridhar RK; Chandru R; Pavithra V; Raj DR; Dev B; Sundaram S; Ramya R
J Cancer Res Ther; 2022; 18(6):1738-1742. PubMed ID: 36412438
[TBL] [Abstract] [Full Text] [Related]
16. Circulating LncRNAs landscape as potential biomarkers in breast cancer.
Pourramezan Z; Attar FA; Yusefpour M; Azizi M; Oloomi M
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1722. PubMed ID: 36274054
[TBL] [Abstract] [Full Text] [Related]
17. Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
Grootes I; Keeman R; Blows FM; Milne RL; Giles GG; Swerdlow AJ; Fasching PA; Abubakar M; Andrulis IL; Anton-Culver H; Beckmann MW; Blomqvist C; Bojesen SE; Bolla MK; Bonanni B; Briceno I; Burwinkel B; Camp NJ; Castelao JE; Choi JY; Clarke CL; Couch FJ; Cox A; Cross SS; Czene K; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Ernst K; Evans DG; Figueroa JD; Fink V; Floris G; Fox S; Gabrielson M; Gago-Dominguez M; García-Sáenz JA; González-Neira A; Haeberle L; Haiman CA; Hall P; Hamann U; Harkness EF; Hartman M; Hein A; Hooning MJ; Hou MF; Howell SJ; ; ; Ito H; Jakubowska A; Janni W; John EM; Jung A; Kang D; Kristensen VN; Kwong A; Lambrechts D; Li J; Lubiński J; Manoochehri M; Margolin S; Matsuo K; Taib NAM; Mulligan AM; Nevanlinna H; Newman WG; Offit K; Osorio A; Park SK; Park-Simon TW; Patel AV; Presneau N; Pylkäs K; Rack B; Radice P; Rennert G; Romero A; Saloustros E; Sawyer EJ; Schneeweiss A; Schochter F; Schoemaker MJ; Shen CY; Shibli R; Sinn P; Tapper WJ; Tawfiq E; Teo SH; Teras LR; Torres D; Vachon CM; van Deurzen CHM; Wendt C; Williams JA; Winqvist R; Elwood M; Schmidt MK; García-Closas M; Pharoah PDP
Eur J Cancer; 2022 Sep; 173():178-193. PubMed ID: 35933885
[TBL] [Abstract] [Full Text] [Related]
18. Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human cancer Cell Lines.
Zhang Z; Golomb L; Meyerson M
Cancer Res; 2022 Jun; 82(11):2171-2184. PubMed ID: 35395071
[TBL] [Abstract] [Full Text] [Related]
19. BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome.
Blatnik A; Ribnikar D; Šetrajčič Dragoš V; Novaković S; Stegel V; Grčar Kuzmanov B; Boc N; Perić B; Škerl P; Klančar G; Krajc M
Breast Cancer; 2022 Sep; 29(5):921-927. PubMed ID: 35381901
[TBL] [Abstract] [Full Text] [Related]
20. Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers.
Sivadas A; Kok VC; Ng KL
Breast Cancer Res Treat; 2022 Jun; 193(2):361-379. PubMed ID: 35348974
[TBL] [Abstract] [Full Text] [Related]
[Next]
